Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.63 USD | -1.60% | -3.89% | -8.08% |
Financials (USD)
Sales 2024 * | 2.76B | Sales 2025 * | 3.14B | Capitalization | 16.82B |
---|---|---|---|---|---|
Net income 2024 * | 306M | Net income 2025 * | 484M | EV / Sales 2024 * | 5.77 x |
Net cash position 2024 * | 883M | Net cash position 2025 * | 1.36B | EV / Sales 2025 * | 4.93 x |
P/E ratio 2024 * |
55.8
x | P/E ratio 2025 * |
34.4
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | -1.60% | ||
1 week | -3.89% | ||
Current month | +1.48% | ||
1 month | +3.94% | ||
3 months | -3.92% | ||
6 months | +7.31% | ||
Current year | -8.08% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | 0.00% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 88.63 | -1.60% | 1,778,647 |
24-04-18 | 90.07 | -0.44% | 944,850 |
24-04-17 | 90.47 | -0.44% | 1,282,481 |
24-04-16 | 90.87 | -0.70% | 1,235,787 |
24-04-15 | 91.51 | -0.77% | 1,942,193 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.08% | 16.82B | |
-5.99% | 83.66B | |
+2.76% | 40.41B | |
-24.88% | 28.26B | |
+53.61% | 24.53B | |
-33.74% | 13.39B | |
-16.63% | 11.75B | |
-11.19% | 11.69B | |
-2.25% | 8.13B | |
+1.05% | 7.55B |
- Stock Market
- Equities
- BMRN Stock